Research programme: antibody-based therapeutics - NB Health Laboratory

Drug Profile

Research programme: antibody-based therapeutics - NB Health Laboratory

Alternative Names: Anti EP4 receptor antibody - NB Health Laboratory; P 001 - NB Health Laboratory; P 007; P 013; Respiratory diseases and inflammation therapeutic - NB Health Laboratory

Latest Information Update: 13 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NB Health Laboratory
  • Class Anti-inflammatories; Antibodies; Monoclonal antibodies
  • Mechanism of Action Beta arrestin inhibitors; Beta-arrestin stimulants; Cyclic AMP receptor modulators; G protein-coupled receptor antagonists; Interleukin 17 receptor modulators; Prostaglandin E EP4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Immunological disorders; Inflammation; Pain; Respiration disorders

Most Recent Events

  • 13 Sep 2016 Research programme: antibody-based therapeutics - NB Health Laboratory is available for licensing in Japan as of 13 Sep 2016. http://www.nbhl.co.jp
  • 13 Sep 2016 NB Health laboratory has patent protection for P 001 in Japan and Europe (NB Health laboratory pipeline, September 2016)
  • 13 Sep 2016 NB Health laboratory has patent protection for P 007 in Japan and USA (NB Health laboratory pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top